User Image Cart Icon 0 Search Image

Anti Atherogenic

  1. The anti-carcinogenic andย ANTI-ATHE ROGENICeffects of lycopene: a review
  2. The metabolism andย ANTI-ATHEROGENICproperties of HDL
  3. The anti-inflammatory and potentialย ANTI-ATHEROGENICeffect of insulin: a new paradigm
  4. Anti-inflammatory andย ANTI-ATHEROGENICproperties of adiponectin
  5. ANTI-ATHEROGENICeffects of resveratrol
  6. The forgotten face of regular physical exercise: a โ€˜naturalโ€™ANTI-ATHEROGENICactivity
  7. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or anย ANTI-ATHEROGENICmediator?
  8. Interferon-ฮณ and atherosclerosis: pro-orย ANTI-ATHEROGENIC?
  9. Thiazolidinediones as antiโ€inflammatory and antiโ€atherogenic agents
  10. Protein composition determines theย ANTI-ATHEROGENICproperties of HDL in transgenic mice
  11. Resveratrol andย ANTI-ATHEROGENICeffects
  12. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in anย ANTI-ATHEROGENIClipid profile
  13. ANTI-ATHEROGENICeffects of seabuckthorn (Hippophaea rhamnoides) seed oil
  14. Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic andย ANTI-ATHEROGENICadipokine
  15. Nuts:ย ANTI-ATHEROGENICfood?
  16. ANTI-ATHEROGENICmechanisms of high density lipoprotein: effects on myeloid cells
  17. ANTI-ATHEROGENICand anti-angiogenic activities of polyphenols from propolis
  18. Evaluation of antioxidant andย ANTI-ATHEROGENICproperties of Glycyrrhiza glabra root using in vitro models
  19. Advanced glycation of apolipoprotein AI impairs itsย ANTI-ATHEROGENICproperties
  20. Insights into the molecular mechanisms of theย ANTI-ATHEROGENICactions of flavonoids in normal and obese mice
  21. ANTI-ATHEROGENICeffect of coenzyme Q10 in apolipoprotein E gene knockout mice
  22. Heme oxygenaseโ€“carbon monoxide signalling pathway in atherosclerosis:ย ANTI-ATHEROGENICactions of bilirubin and carbon monoxide?
  23. Antioxidant andย ANTI-ATHEROGENICactivities of olive oil phenolics
  24. Natural compounds asย ANTI-ATHEROGENICagents: Clinical evidence for improved cardiovascular outcomes
  25. Antioxidant andย ANTI-ATHEROGENICactivities of three Piper species on atherogenic diet fed hamsters
  26. Anti-inflammatory andย ANTI-ATHEROGENICeffects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice
  27. Evaluation of theย ANTI-ATHEROGENICpotential of chrysin in Wistar rats
  28. The hyperpolarizing impact of glycine on endothelial cells may beย ANTI-ATHEROGENIC
  29. Vitamin E analogs: a new class of multiple action agents with anti-neoplastic andย ANTI-ATHEROGENICactivity
  30. Possible antiโ€atherogenic effect of kolaviron (a Garcinia kola seed extract) in hypercholesterolaemic rats
  31. Eicosapentaenoic acid-enriched high-density lipoproteins exhibitย ANTI-ATHEROGENICproperties
  32. Cardioprotective effects of high-density lipoprotein beyond itsย ANTI-ATHEROGENICaction
  33. ANTI-ATHEROGENICand anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus
  34. ANTI-ATHEROGENICeffects of 17ฮฒ-estradiol
  35. ANTI-ATHEROGENICeffect of nuts: is the answer NO?
  36. Anย ANTI-ATHEROGENICeffect of Schistosoma mansoni infections in mice associated with a parasite-induced lowering of blood total cholesterol
  37. Naringenin derivatives asย ANTI-ATHEROGENICagents
  38. Apolipoprotein mimetic peptides: Mechanisms of action asย ANTI-ATHEROGENICagents
  39. Sphingosine 1-phosphate inducedย ANTI-ATHEROGENICand atheroprotective M2 macrophage polarization through IL-4
  40. ANTI-ATHEROGENICEffect of Laminar Shear Stress via Nrf2 Activation
  41. Regulation of pro-andย ANTI-ATHEROGENICcytokines
  42. Neuronal nitric oxide synthase as a novelย ANTI-ATHEROGENICfactor
  43. ANTI-ATHEROGENICeffect of insulin in vivo
  44. Phenolic compounds and theย ANTI-ATHEROGENICeffect of bee bread in high-fat diet-induced obese rats
  45. ANTI-ATHEROGENICeffect of citrus flavonoids, naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits
  46. A study of anti-hyperlipidemia, hypolipedimic andย ANTI-ATHEROGENICactivity of fruit of Emblica officinalis (amla) in high fat fed albino rats
  47. ANTI-ATHEROGENICproperties of date vs. pomegranate polyphenols: the benefits of the combination
  48. ANTI-ATHEROGENICeffects of orlistat on obesity-induced vascular oxidative stress rat model
  49. Phytosterol supplementation could improve atherogenic andย ANTI-ATHEROGENICapolipoproteins: a systematic review and doseโ€“response meta-analysis of randomized โ€ฆ
  50. Apolipoprotein AI mimetic peptide helix number and helix linker influence potentiallyย ANTI-ATHEROGENICproperties
  51. Placental secretion of apolipoprotein A1 and E: theย ANTI-ATHEROGENICimpact of the placenta
  52. An experimental evaluation of theย ANTI-ATHEROGENICpotential of the plant, Piper betle, and its active constitutent, eugenol, in rats fed an atherogenic diet
  53. ANTI-ATHEROGENICactivity of ethanolic fraction of Terminalia arjuna bark on hypercholesterolemic rabbits
  54. Atherogenic andย ANTI-ATHEROGENICfactors in the human diet
  55. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins:ย ANTI-ATHEROGENICrole for paraoxonase-2
  56. Antiโ€atherogenic effect of statins: role of nitric oxide, peroxynitrite and haem oxygenaseโ€1
  57. ANTI-ATHEROGENICpotential of jujube, saffron and barberry: anti-diabetic and antioxidant actions
  58. Resveratrol mediatesย ANTI-ATHEROGENICeffects on cholesterol flux in human macrophages and endothelium via PPARฮณ and adenosine
  59. Nitric oxide enhances the anti-inflammatory andย ANTI-ATHEROGENICactivity of atorvastatin in a mouse model of accelerated atherosclerosis
  60. Antiโ€Atherogenic Effect of Stem Cell Nanovesicles Targeting Disturbed Flow Sites
  61. Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potentialย ANTI-ATHEROGENICfunction?
  62. Glucose lowering andย ANTI-ATHEROGENICeffects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors
  63. Anti-oxidant andย ANTI-ATHEROGENICproperties of liposomal glutathione: studies in vitro, and in the atherosclerotic apolipoprotein E-deficient mice
  64. Role of sphingosine 1-phosphate inย ANTI-ATHEROGENICactions of high-density lipoprotein
  65. Altered activities ofย ANTI-ATHEROGENICenzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice
  66. ANTI-ATHEROGENICeffects of the methanol extract of Sorbus cortex in atherogenic-diet rats
  67. Antiโ€atherogenic effect of berberine on LXRฮฑโ€ABCA1โ€dependent cholesterol efflux in macrophages
  68. AMPK activation enhances theย ANTI-ATHEROGENICeffects of high density lipoproteins in apoEโˆ’/โˆ’ mice
  69. โ€ฆ (NMN) supplementation promotes anti-aging miRNA expression profile in the aorta of aged mice, predicting epigenetic rejuvenation andย ANTI-ATHEROGENICeffects
  70. Taurine supplementation hasย ANTI-ATHEROGENICand anti-inflammatory effects before and after incremental exercise in heart failure
  71. Structural evidence ofย ANTI-ATHEROGENICmicroRNAs
  72. Inhibition of cytokine-induced vascular cell adhesion molecule-1 expression; possible mechanism forย ANTI-ATHEROGENICeffect of Agastache rugosa
  73. Antiโ€atherogenic and antiโ€inflammatory properties of glucagonโ€like peptideโ€1, glucoseโ€dependent insulinotropic polypepide, and dipeptidyl peptidaseโ€4 inhibitors in โ€ฆ
  74. A review of the cardiovascular andย ANTI-ATHEROGENICeffects of ghrelin
  75. ANTI-ATHEROGENICproperty of ferulic acid in apolipoprotein E-deficient mice fed Western diet: comparison with clofibrate
  76. Aminoguanidine has anย ANTI-ATHEROGENICeffect in the cholesterol-fed rabbit
  77. Evaluation of the in vitroย ANTI-ATHEROGENICactivities of goat milk and goat dairy products
  78. In silico design ofย ANTI-ATHEROGENICbiomaterials
  79. ANTI-ATHEROGENICactivity of polyphenol-rich extract from bee pollen
  80. Regulation ofย ANTI-ATHEROGENICapolipoprotein M gene expression by the orphan nuclear receptor LRH-1
  81. Vitamin E: the evidence for anย ANTI-ATHEROGENICrole.
  82. ANTI-ATHEROGENICeffect of hydrogen sulfide by over-expression of cystathionine gamma-lyase (CSE) gene
  83. Overexpression of STARD3 in human monocyte/macrophages induces anย ANTI-ATHEROGENIClipid phenotype
  84. In vitroย ANTI-ATHEROGENICproperties of traditional Greek cheese lipid fractions
  85. ANTI-ATHEROGENICeffect of 10% supplementation of anchovy (Engraulis encrasicolus) waste protein hydrolysates in ApoE-deficient mice
  86. Hypolipidemic andย ANTI-ATHEROGENICeffects of long-term Cholestin (Monascus purpureus-fermented rice, red yeast rice) in cholesterol fed rabbits
  87. ANTI-ATHEROGENICeffects of centipede acidic protein in rats fed an atherogenic diet
  88. In vitro Antiโ€atherogenic Properties of Nโ€Heterocyclic Carbene Aurate (I) Compounds
  89. Phytochemical analysis ofย ANTI-ATHEROGENICconstituents of Xue-Fu-Zhu-Yu-Tang using HPLC-DAD-ESI-MS
  90. A genome scan for loci influencingย ANTI-ATHEROGENICserum bilirubin levels
  91. Hypolipidemic and antiโ€atherogenic activities of crude polysaccharides from abalone viscera
  92. Enzymatic synthesis of phytosteryl docosahexaneates and evaluation of theirย ANTI-ATHEROGENICeffects in apo-E deficient mice
  93. Anti-thrombotic andย ANTI-ATHEROGENICaction of eicosapentaenoic acid
  94. PPAR Activity in the Vessel Wall:ย ANTI-ATHEROGENICProperties
  95. โ€ฆ intima-media thickness by reducing small dense low-density lipoproteins in a real-world setting of patients with type 2 diabetes: A novelย ANTI-ATHEROGENICโ€ฆ
  96. Apoprotein AI mimetic peptides and their potentialย ANTI-ATHEROGENICmechanisms of action
  97. Date (Phoenix dactylifera L.) Fruit Soluble Phenolics Composition andย ANTI-ATHEROGENICProperties in Nine Israeli Varieties
  98. Enhanced CD36 expression changes the role of Nrf2 activation fromย ANTI-ATHEROGENICto pro-atherogenic in apoE-deficient mice
  99. The effect of intakes of fish and Camelina sativa oil on atherogenic andย ANTI-ATHEROGENICfunctions of LDL and HDL particles: A randomized controlled trial
  100. Theย ANTI-ATHEROGENICeffects of berberine on foam cell formation are mediated through the upregulation of sirtuin 1
  101. The endothelium as a target forย ANTI-ATHEROGENICtherapy: a focus on the epigenetic enzymes EZH2 and SIRT1
  102. ANTI-ATHEROGENICeffects of CD36-targeted epigallocatechin gallate-loaded nanoparticles
  103. Ursodeoxycholic acid (UDCA) exertsย ANTI-ATHEROGENICeffects by inhibiting RAGE signaling in diabetic atherosclerosis
  104. ANTI-ATHEROGENICactions of high-density lipoprotein through sphingosine 1-phosphate receptors and scavenger receptor class B type I
  105. ANTI-ATHEROGENICeffects of vaspin on human aortic smooth muscle cell/macrophage responses and hyperlipidemic mouse plaque phenotype
  106. ANTI-ATHEROGENICeffect of soya and rice-protein isolate, compared with casein, in apolipoprotein E-deficient mice
  107. Screening ofย ANTI-ATHEROGENICsubstances from insect resources
  108. ฮฒ2-Integrin and lipid modifications indicate a non-antioxidant mechanism for theย ANTI-ATHEROGENICeffect of dietary coenzyme Q10
  109. ANTI-ATHEROGENICeffects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model
  110. HDL slowing down endothelial progenitor cells senescence: a novelย ANTI-ATHEROGENICproperty of HDL
  111. Functional interplay between liver X receptor and AMPโ€activated protein kinase ฮฑ inhibits atherosclerosis in apolipoprotein Eโ€deficient miceโˆ’ a new antiโ€atherogenic โ€ฆ
  112. Estrogen regulation of the scavenger receptor class B gene:ย ANTI-ATHEROGENICor steroidogenic, is there a priority?
  113. Physicochemical characteristics of rapidly dried onion powder and itsย ANTI-ATHEROGENICeffect on rats fed high-fat diet
  114. Fish and lifestyle-related disease prevention: experimental and epidemiological evidence forย ANTI-ATHEROGENICpotential of taurine.
  115. The beneficial effect of tamoxifen on serum lipoprotein-A levels: an additionalย ANTI-ATHEROGENICproperty.
  116. In vivoย ANTI-ATHEROGENICproperties of cultured gilthead sea bream (Sparus aurata) polar lipid extracts in hypercholesterolaemic rabbits
  117. ANTI-ATHEROGENICproperties of vitamin E, aspirin, and their combination
  118. Hypolipidemic andย ANTI-ATHEROGENICeffect of aqueous extract leaves of Ficus glumosa (Moraceae) in rats
  119. ANTI-ATHEROGENICeffects of methotrexate carried by a lipid nanoemulsion that binds to LDL receptors in cholesterol-fed rabbits
  120. Nicotinic acid hasย ANTI-ATHEROGENICand anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities
  121. Omegaโ€“3 fatty acids, inflammation and angiogenesis: nutrigenomic effects as an explanation forย ANTI-ATHEROGENICand anti-inflammatory effects of fish and fish oils
  122. ANTI-ATHEROGENICeffects of the aqueous extract of rhubarb in rats fed an atherogenic diet
  123. Ursodeoxycholic acid (UDCA) exertsย ANTI-ATHEROGENICeffects by inhibiting endoplasmic reticulum (ER) stress induced by disturbed flow
  124. ANTI-ATHEROGENICmodification of serum lipoprotein function in patients with rheumatoid arthritis after tocilizumab treatment, a pilot study
  125. Inhibition of cytokine-induced IฮบB kinase activation as a mechanism contributing to theย ANTI-ATHEROGENICactivity of tilianin in hyperlipidemic mice
  126. Caveolin-1 regulates theย ANTI-ATHEROGENICproperties of macrophages
  127. Theย ANTI-ATHEROGENICproperties of HDL particles
  128. Bioactive pigments of monascus purpureus attributed to antioxidant, HMG-CoA reductase inhibition andย ANTI-ATHEROGENICfunctions
  129. Evaluation of in vitro antioxidant andย ANTI-ATHEROGENICproperties of selected Siddha polyherbal decoctions
  130. Cell-mediated lipoprotein transport: A novelย ANTI-ATHEROGENICconcept
  131. Conditional linkage and genome-wide association studies identify UGT1A1 as a major gene forย ANTI-ATHEROGENICserum bilirubin levelsโ€”the Framingham Heart Study
  132. ANTI-ATHEROGENICeffects of a mixture of ascorbic acid, lysine, proline, arginine, cysteine, and green tea phenolics in human aortic smooth muscle cells
  133. A novelย ANTI-ATHEROGENICrole for COX-2โ€”potential mechanism for the cardiovascular side effects of COX-2 inhibitors
  134. Antiโ€atherogenic effects of highโ€density lipoprotein on nitric oxide synthesis in the endothelium
  135. Mechanisms of action of theย ANTI-ATHEROGENICeffect of magnesium: lessons from a mouse model.
  136. ANTI-ATHEROGENICeffects of statins: Impact on angiopoietin-2 release from endothelial cells
  137. Long term anti-diabetic, anti-hyperlipidaemic andย ANTI-ATHEROGENICeffects of Carica papaya leaves in streptozotocin diabetic rats.
  138. MEK1/2 inhibitors activate macrophage ABCG1 expression and reverse cholesterol transportโ€”Anย ANTI-ATHEROGENICfunction of ERK1/2 inhibition
  139. Endothelial lipase exerts itsย ANTI-ATHEROGENICeffect through increased catabolism of ฮฒ-VLDLs
  140. High-density lipoprotein affects antigen presentation by interfering with lipid raft: a promisingย ANTI-ATHEROGENICstrategy
  141. Hypolipidemic andย ANTI-ATHEROGENICeffect of sulphated polysaccharides from the green alga Ulva fasciata
  142. The anti-osteoporotic andย ANTI-ATHEROGENICeffects of alendronate and simvastatin in ovariectomized rats fed high fat diet: a comparative study of combination therapy โ€ฆ
  143. โ€ฆ deficiency (ASMD): Further clearance of hepatic sphingomyelin is associated with additional improvements in pro-andย ANTI-ATHEROGENIClipid profiles after 42 โ€ฆ
  144. The hyperlipemic hamsterโ€a model for testing the antiโ€atherogenic effect of amlodipine
  145. ANTI-ATHEROGENICproperties of allium ursinum liophylisate: Impact on lipoprotein homeostasis and cardiac biomarkers in hypercholesterolemic rabbits
  146. Treatment with PCSK9 inhibitors induces a moreย ANTI-ATHEROGENICHDL lipid profile in patients at high cardiovascular risk
  147. ANTI-ATHEROGENICeffects of 3, 4-dihydroxy hydrocinnamides
  148. Theย ANTI-ATHEROGENICproperties of sesamin are mediated via improved macrophage cholesterol efflux through PPARฮณ1-LXRฮฑ and MAPK signaling
  149. ANTI-ATHEROGENICproperties of resveratrol: 4-week resveratrol administration associated with serum concentrations of SIRT1, adiponectin, S100A8/A9 and โ€ฆ
  150. Glucocorticoid receptor-mediated upregulation of human CYP27A1, a potentialย ANTI-ATHEROGENICenzyme
  151. Antiโ€oxidative, antiโ€inflammatory and antiโ€atherogenic effects of Dandelion (Taraxacum officinale) extracts in C57BL/6 mice fed atherogenic diet
  152. ANTI-ATHEROGENICeffect of trivalent chromium-loaded CPMV nanoparticles in human aortic smooth muscle cells under hyperglycemic conditions in vitro
  153. 14 Days of supplementation with blueberry extract showsย ANTI-ATHEROGENICproperties and improves oxidative parameters in hypercholesterolemic rats model
  154. Theย ANTI-ATHEROGENICpotential of serum amyloid A peptides.
  155. Effect of Nโ€(pโ€coumaroyl)serotonin and Nโ€feruloylserotonin, major antiโ€atherogenic polyphenols in safflower seed, on vasodilation, proliferation and migration of โ€ฆ
  156. Genistein as a potential inducer of the antiโ€atherogenic enzyme paraoxonaseโ€1: studies in cultured hepatocytes in vitro and in rat liver in vivo
  157. ANTI-ATHEROGENICeffect of BHB-TZD having inhibitory activities on cyclooxygenase and 5-lipoxygenase in hyperlipidemic mice
  158. ANTI-ATHEROGENICeffect of San-Huang-Xie-Xin-Tang, a traditional Chinese medicine, in cultured human aortic smooth muscle cells
  159. ANTI-ATHEROGENICproperties of Deglet Noor date seeds (Phoenix dactylifera) methanol extract on diet-induced hypercholesterolemic rats
  160. Sphingosine kinase inhibition exerts both pro-andย ANTI-ATHEROGENICeffects in low-density lipoprotein receptor-deficient (LDL-Rโˆ’/โˆ’) mice
  161. Apolipoprotein ฮต2 allele is associated with anย ANTI-ATHEROGENIClipoprotein profile in children: the Columbia University BioMarkers Study
  162. โ€ฆ endothelial production of heparan sulfate rich in biologically active heparin-like domains: a potential mechanism for theย ANTI-ATHEROGENICactions of vascular โ€ฆ
  163. Endothelium-dependent hyperpolarization as a remoteย ANTI-ATHEROGENICmechanism
  164. ANTI-ATHEROGENICeffects of the acyl-CoA: cholesterol acyltransferase inhibitor, avasimibe (CI-1011), in cultured primary human macrophages
  165. ANTI-ATHEROGENICeffect of Humulus japonicus in apolipoprotein E-deficient mice
  166. Ginkgo biloba extract (GbE) enhances theย ANTI-ATHEROGENICeffect of cilostazol by inhibiting ROS generation
  167. ANTI-ATHEROGENICantioxidants regulate the expression and function of proteasome ฮฑ-type subunits in human endothelial cells
  168. Probucol and cilostazol exert a combinatorialย ANTI-ATHEROGENICeffect in cholesterol-fed rabbits
  169. Alogliptin: a new dipeptidyl peptidase-4 inhibitor with potentialย ANTI-ATHEROGENICproperties
  170. Evaluation of nicotinic acid as an hypocholesteremic andย ANTI-ATHEROGENICsubstance
  171. Cell culture as a testing system forย ANTI-ATHEROGENICsubstances: a brief communication
  172. Scavenger receptor B-1 emerges asย ANTI-ATHEROGENICcandidate
  173. Treatment for hepatitis C virus with pegylated interferon-ฮฑ plus ribavirin inducesย ANTI-ATHEROGENICeffects on cardiovascular risk biomarkers in HIV-infected and โ€ฆ
  174. Efficient coexpression and secretion ofย ANTI-ATHEROGENIChuman apolipoprotein AI and lecithin-cholesterol acyltransferase by cultured muscle cells using adeno โ€ฆ
  175. Antithrombic andย ANTI-ATHEROGENICeffects of partially defatted flaxseed meal using a laser-induced thrombosis test in apolipoprotein E and low-density lipoprotein โ€ฆ
  176. C-terminal apolipoprotein E-derived peptide, Ep1. B, displaysย ANTI-ATHEROGENICactivity
  177. Theย ANTI-ATHEROGENICcytokine interleukin-33 inhibits the expression of a disintegrin and metalloproteinase with thrombospondin motifs-1,-4 and-5 in human โ€ฆ
  178. Statins but not fibrates improve the atherogenic toย ANTI-ATHEROGENIClipoprotein particle ratio: a randomized crossover study
  179. Evaluation of the in vitroย ANTI-ATHEROGENICproperties of lipid fractions of olive pomace, olive pomace enriched fish feed and gilthead sea bream (Sparus aurata) fed โ€ฆ
  180. 20 (S)-protopanaxadiol saponins mainly contribute to theย ANTI-ATHEROGENICeffects of Panax notoginseng in ApoE deficient mice
  181. ANTI-ATHEROGENICand anti-ischemic potentials of Croton membranaceus observed during sub-chronic toxicity studies
  182. Evaluation of theย ANTI-ATHEROGENICpotential of Egyptian artichoke leaf extract in hypercholesterolemic rats
  183. ANTI-ATHEROGENICeffects of a new thienylacylhydrazone derivative, LASSBio-788, in rats fed a hypercholesterolemic diet
  184. โ€ฆ of a disintegrin and metalloproteinase with thrombospondin motifs 4 in human macrophages is inhibited by theย ANTI-ATHEROGENICcytokine transforming growth โ€ฆ
  185. Theย ANTI-ATHEROGENICaspect of metformin treatment in insulin resistant women with the polycystic ovary syndrome: role of the newly established pro-inflammatory โ€ฆ
  186. APOA-1Milano muteins, orally delivered via genetically modified rice, showย ANTI-ATHEROGENICand anti-inflammatory properties in vitro and in Apoe โ€ฆ
  187. Comparison of cholesterol-lowering efficacy andย ANTI-ATHEROGENICproperties of hydrogenated versus non-hydrogenated (Phytrolโ„ข) tall oil-derived phytosterols in apo โ€ฆ
  188. ANTI-ATHEROGENICeffect of isoflavone through hypolipidemic, anti-oxidative and anti-inflammatory actions in C57BL/6 mice
  189. Androgen receptor-mediated regulation of theย ANTI-ATHEROGENICenzyme CYP27A1 involves the JNK/c-jun pathway
  190. Human plasma paraoxonase (HuPON1): anย ANTI-ATHEROGENICenzyme with organophosphate hydrolase activity
  191. Betulinic acid and fluvastatin exhibits synergistic effect on toll-like receptor-4 mediatedย ANTI-ATHEROGENICmechanism in type II collagen induced arthritis
  192. Theย ANTI-ATHEROGENICeffects of lycopene
  193. The anti-hyperlipemic andย ANTI-ATHEROGENICeffect ofโ€ essentialโ€ phospholipids: a pharmacologic trial
  194. Testing ofย ANTI-ATHEROGENICdrugs and food components on cell cultures: assessment of reliability
  195. Protamine may haveย ANTI-ATHEROGENICpotential by inhibiting the binding of oxidized-low density lipoprotein to LOX-1
  196. ANTI-ATHEROGENICproperties of Kgengwe (Citrullus lanatus) seed powder in low-density lipoprotein receptor knockout mice are mediated through beneficial alterations โ€ฆ
  197. Theย ANTI-ATHEROGENICeffect of dietary soybean protein concentrate in hamsters
  198. Structure and lipid interactions of an anti-inflammatory andย ANTI-ATHEROGENIC10-residue class GโŽ apolipoprotein J peptide using solution NMR
  199. Multiple pathway assessment to predictย ANTI-ATHEROGENICefficacy of drugs targeting macrophages in atherosclerotic plaques
  200. ANTI-ATHEROGENICproperties of emulsified perilla oil (EPO) in apo E KO mice and plasma lipid lowering effects of rice porridge containing EPO in healthy young adults
  201. ANTI-ATHEROGENICeffect of Nepitrin-7-O-glucoside: A flavonoid isolated from Nepeta hindostana via acting on PPARโ€“ฮฑ receptor
  202. ANTI-ATHEROGENICeffects of curcumin in hypercholesterolemic rabbits
  203. Anti-thrombotic andย ANTI-ATHEROGENICaction of eicosapentaenoic acid
  204. Antihypercholesterolemic andย ANTI-ATHEROGENICeffects of lyophilized aqueous extract of Globularia alypum leaves in rats fed a high-cholesterol diet
  205. Inhibition of plasma lipid peroxidation byย ANTI-ATHEROGENICantioxidant BO-653, 2, 3-dihydro-5-hydroxy-4, 6-di-tert-butyl-2, 2-dipentylbenzofuran
  206. Antioxidant andย ANTI-ATHEROGENICProperties of Prosopis strombulifera and Tessaria absinthioides Aqueous Extracts: Modulation of NADPH Oxidase-Derived โ€ฆ
  207. On theย ANTI-ATHEROGENICeffect of the antioxidant BHT in cholesterol-fed rabbits: inverse relation between serum triglycerides and atheromatous lesions
  208. Hypolipidemic andย ANTI-ATHEROGENICActivity of Aqueous Extract of Leaves of Lagenaria siceraria in Wistar Rats
  209. ANTI-ATHEROGENICeffects of high density lipoproteins: Mechanisms
  210. Ritonavir exhibitsย ANTI-ATHEROGENICproperties on vascular smooth muscle cells
  211. Hypocholesterolaemic andย ANTI-ATHEROGENICEffects of Palm-Based Oils (NoveLin I and NoveLin II) in Cholesterol-Fed Rabbits
  212. ANTI-ATHEROGENICeffects of resveratrol via liver X receptor ฮฑ-dependent upregulation of ATP-binding cassette transporters A1 and G1 in macrophages
  213. ANTI-ATHEROGENICeffects of an egg yolk-enriched garlic supplement
  214. Theย ANTI-ATHEROGENICeffects of thiazolidinediones
  215. High density lipoproteins: theย ANTI-ATHEROGENICfraction
  216. Biochemical mechanism of insulin sensitization, lipid modulation andย ANTI-ATHEROGENICpotential of PPAR ฮฑ/ฮณ dual agonist: Ragaglitazar
  217. ANTI-ATHEROGENICEffects of a Phenol-Rich Fraction from Brazilian Red Wine (Vitis labrusca L.) in Hypercholesterolemic Low-Density Lipoprotein Receptor Knockout โ€ฆ
  218. โ€ฆ infiltration of macrophages and inhibited activation of nuclear factor-kappa B in blood vessels: a possible mechanism for theย ANTI-ATHEROGENICeffects of losartan
  219. Inhibition of LDL oxidation and inflammasome assembly by nitroaliphatic derivatives. Potential use as anti-inflammatory andย ANTI-ATHEROGENICagents
  220. Significant deterioration ofย ANTI-ATHEROGENICefficacy of nebivolol in a double (apolipoprotein E and endothelial nitric oxide synthase) knockout mouse model of โ€ฆ
  221. Are calcium ion antagonists effectiveย ANTI-ATHEROGENICagents?
  222. ANTI-ATHEROGENICaction of Panax ginseng in rats and in patients with hyperlipidemia
  223. Incretins in type 2 diabetes mellitus: cardiovascular andย ANTI-ATHEROGENICeffects beyond glucose lowering
  224. Theย ANTI-ATHEROGENICactivity of beauveriolide derivative BVD327, a sterol O-acyltransferase 2-selective inhibitor, in apolipoprotein e knockout mice
  225. ANTI-ATHEROGENICeffects of fermented fresh coffee bean, soybean and rice bran extracts
  226. Selective peroxisome proliferator-activated receptor ฮด isosteric selenium agonists as potentย ANTI-ATHEROGENICagents in vivo
  227. The C17-OH Group of ล’stradiol: Relationships between itsย ANTI-ATHEROGENICand Endocrine Actions
  228. ANTI-ATHEROGENICeffects of phytosteryl oleates in apo-E deficient mice
  229. ANTI-ATHEROGENICpeptide Ep1. B derived from apolipoprotein E induces tolerogenic plasmacytoid dendritic cells
  230. Potentialย ANTI-ATHEROGENICcell action of the naturally occurring 4-O-methyl derivative of gallic acid on Ang II-treated macrophages
  231. The pro-inflammatory effect of uraemia overrules theย ANTI-ATHEROGENICpotential of immunization with oxidized LDL in apoEโˆ’/โˆ’ mice
  232. ANTI-ATHEROGENICeffects of fibrates in type 2 diabetes
  233. Folate and vitamin B12 in morbid obesity: the influence of folate onย ANTI-ATHEROGENIClipid profile
  234. ANTI-ATHEROGENICproperties of fibrates may be largely due to their anti-inflammatory effects
  235. Atherogenic andย ANTI-ATHEROGENICplasma lipoproteins modulate secretion of prostanoids by endothelial cells in vitro
  236. Different functional and structural characteristics between ApoA-I and ApoA-4 in lipid-free and reconstituted HDL state: ApoA-4 showed lessย ANTI-ATHEROGENICโ€ฆ
  237. ANTI-ATHEROGENICeffects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice
  238. ANTI-ATHEROGENICRole of Peroxisome Proliferator-Activated Receptor Ligands
  239. Antiโ€“Atherogenic Activity of Ethanol Extract of Buccholzia coriacea Seeds on Hypercholesterolemic Rats.
  240. Cholesterol-lowering andย ANTI-ATHEROGENICeffects of oats in mice
  241. Lack of difference among progestins on the antiโ€atherogenic effect of ethinyl estradiol: a rabbit study
  242. Gemfibrozil and its combination with metformin on pleiotropic effect on IL-10 and adiponectin andย ANTI-ATHEROGENICtreatment in insulin resistant type 2 diabetes โ€ฆ
  243. The beneficial effects of high-density lipoprotein on adipocytes may relate to itsย ANTI-ATHEROGENICproperties
  244. Theย ANTI-ATHEROGENICmechanism of action of physical training in patients with coronary heart disease
  245. Adiponectin-a novelย ANTI-ATHEROGENICfactor in the metabolic syndrome: mechanisms of action and therapeutic potential
  246. ANTI-ATHEROGENICproperties of extra virgin olive Oil
  247. Observation of Inflammatory Marker Levels in Sprague-Dawley Rats with Youngyopaedoc-san-relatedย ANTI-ATHEROGENICEffect
  248. Inhibition of LDL oxidation and oxidized LDL-induced foam cell formation in RAW 264.7 cells showย ANTI-ATHEROGENICproperties of a foliar methanol extract of โ€ฆ
  249. Inhibition Effect of 3-(4โ€ฒ-hydroxyl-3โ€ฒ,5โ€ฒ-dimethoxyphenyl)Propionic Acid in Kimchi withย ANTI-ATHEROGENICActivity on the Accumulation of Lipids in the Organs of ApoE(-/-) โ€ฆ
  250. HO-1, a new target of PPARฮด with โ€˜ANTI-ATHEROGENICโ€˜properties: is it the one?
  251. ANTI-ATHEROGENICeffect and its mechanisms of soluble egg antigen of schistosomia japonicum in ApoE-/-mice
  252. โ€ฆ in the binding to the protein core of biglycan of the vascular extracellular matrix: potential relationship between retention andย ANTI-ATHEROGENICproperties of this โ€ฆ
  253. Additiveย ANTI-ATHEROGENICeffect of thromboxane receptor antagonism with 12/15lipoxygenase gene disruption in apolipoprotein E-deficient mice
  254. Interleukin-11: a neglected cytokine withย ANTI-ATHEROGENICproperties?
  255. Mouse models of experimental atherosclerosis as a tool for checking a putativeย ANTI-ATHEROGENICaction of drugs
  256. Hypolipidemic andย ANTI-ATHEROGENICeffects of vanadium in high-fat diet rabbits.
  257. โ€ฆ E knockout mice: an experimental model to study inflammatory mechanisms of atherosclerosis and to screen a putativeย ANTI-ATHEROGENICproperties of drugs
  258. Antiโ€inflammatory and antiโ€atherogenic effects of adiponectin in patients with rheumatoid arthritis following antiโ€TNF therapy
  259. Characteristics of the lipid composition of atherogenic andย ANTI-ATHEROGENICserum lipoproteins in patients with bronchial asthma
  260. Theย ANTI-ATHEROGENICrole of exercise is associated with the attenuation of bone marrow-derived macrophage activation and migration in hypercholesterolemic โ€ฆ
  261. Sardine purified proteins improve blood pressure, glycemic control,ย ANTI-ATHEROGENICmetabolic pathways and antioxidant capacity in obese rats
  262. Doesย ANTI-ATHEROGENICestradiol valerate treatment cause adverse effects on liver and uterus in NZW rabbits?
  263. Cross-talk between exogenous statins and endogenous high-density lipoprotein in anti-inflammatory andย ANTI-ATHEROGENICactions
  264. Theย ANTI-ATHEROGENICActivity of Artemisia, Thyme & Soya bean
  265. P58 Potentialย ANTI-ATHEROGENICeffects of hydrogen-sulfide releasing molecules
  266. ANTI-ATHEROGENICeffect of Ca2+-antagonists
  267. Ezetimibeโ€“new antiโ€atherogenic properties?
  268. Pre-clinical evaluation of the hypotensive andย ANTI ATHEROGENICactivity of hydroethanolic extract of Eribroma oblongum (Malvaceae) stem bark on wistar rats models
  269. The Effects ofย ANTI-ATHEROGENICProperties of Beverage of the Date Seeds (Phoenix Dactilifera L.) In Pre-Menopause Women: A Study Of Indonesian Women
  270. ANTI-ATHEROGENICAction of โ€œCardiproโ€-A Herbal Proprietary Formulation
  271. โ€ฆ (NMN) supplementation promotes anti-aging miRNA expression profile in the aorta of aged mice, predicting epigenetic rejuvenation andย ANTI-ATHEROGENICeffects.
  272. Lactobacillus fermentum ME-3โ€“a probiotic with potential forย ANTI-ATHEROGENIC, anti-oxidative and anti-diabetic application
  273. Demonstration of an add-on effect of probucol and cilostazol on the statin-inducedย ANTI-ATHEROGENICeffects
  274. The adenosine A2A receptor agonist UK-432,097 stimulates expression ofย ANTI-ATHEROGENICreverse cholesterol transport proteins
  275. Metabolic andย ANTI-ATHEROGENICeffects of long-term benfluorex in dyslipidemic insulin-resistant sand rats (Psammomys obesus)
  276. ANTI-ATHEROGENICeffects of supplementation with vitamin B6 (Pyridoxine) in albino rats
  277. Theย ANTI-ATHEROGENICeffects of eicosapentaenoic and docosahexaenoic acid are dependent on the stage of THP-1 macrophage differentiation
  278. ANTI-ATHEROGENICproperties of high-density lipoproteins in psychiatric patients before and after two months of atypical anti-psychotic therapy
  279. ANTI-ATHEROGENICactivity of wild grape (Vitis thunbergii) extract antagonizing smooth muscle cell proliferation and migration promoted by neighboring macrophages
  280. The role of 15-lipoxygenase in atherogenesis. Pro-and/orย ANTI-ATHEROGENICaction
  281. ANTI-ATHEROGENICdrugs
  282. Comparativeย ANTI-ATHEROGENICEffects of a Single Intravenous Injection of rAAV8 Or rAAV2 Encoding Apo A-IMilano Gene
  283. Anti-inflammatory andย ANTI-ATHEROGENICrole of BMP receptor II in atherosclerosis
  284. ANTI-ATHEROGENICeffect of green tea product through hypolipidemic and anti-oxidative action in ovariectomized rats
  285. Immunomodulatory activity ofย ANTI-ATHEROGENICdrugs: effects on blastogenesis, humoral response, delayed hypersensitivity and passive anaphylaxis by immune โ€ฆ
  286. How to use ezetimibe as anย ANTI-ATHEROGENICagent via inhibition of rho-Kinase
  287. Bone marrow angiotensin AT2 receptor deficiency aggravates atherosclerosis development by eliminating macrophage liver X receptor-mediatedย ANTI-ATHEROGENICโ€ฆ
  288. Multi-functional aspects of high density lipoprotein as anย ANTI-ATHEROGENIClipoprotein in vivo: evidence from in vitro experiments using macrophages
  289. ANTI-ATHEROGENICeffects of cryopreserved preparation of fetoplacental complex in experimental atherosclerosis
  290. Re-Programming Atherosclerotic Plaque Macrophages Towards Anย ANTI-ATHEROGENICPhenotype
  291. P5330 Evaluating lipid-lowering andย ANTI-ATHEROGENICeffect of injectable Curcumin in a rabbit model of atherosclerosis
  292. Mechanisms ofย ANTI-ATHEROGENICaction of probucol
  293. Concurrent training promoted sustainedย ANTI-ATHEROGENICbenefits in the fasting plasma triacylglycerolemia of postmenopausal women at 1-year follow-up
  294. Possibleย ANTI-ATHEROGENICeffects of emodin, an anthraquinone from Chinese herbs and Aspergillus and Penicillium fungi.
  295. Approaches for the Design of Novelย ANTI-ATHEROGENICCompounds
  296. Antiโ€Atherogenic Effects of Lesionโ€Targeted Epigallocatechin Gallate (EGCG)โ€Loaded Nanoparticles
  297. Antioxidant andย ANTI-ATHEROGENICProperties of Hawthorn Vinegar in Drosophila melanogaster Fed a High-Fat Diet.
  298. Methotrexate improves pro-andย ANTI-ATHEROGENICgenomic expression in psoriatic skin
  299. Antiโ€Atherogenic Potential of Edible Mushrooms
  300. Comparative study of hydrochlorothiazide and indapamide on theย ANTI-ATHEROGENICpotential of losartan in cholesterol fed rat
  301. ANTI-ATHEROGENICEffect of Green Tea
  302. ANTI-ATHEROGENICFUNCTIONS OF HIGH DENSITY LIPOPROTEINS
  303. Effect of Aqueous Seed Extract of Carica Papaya on Lipid Profile and Antiโ€Atherogenic Index of Wistar Rat Following Cholesterol Administration
  304. Evaluation ofย ANTI-ATHEROGENICproperties of ezetimibe using 3H-labeled LDL and 99mTc-cAbVCAM1-5 SPECT imaging in ApoE-/-mice fed a paigen diet
  305. Lecithin cholesterol acyltransferase: an anti-or pro-atherogenic factor?
  306. Anti-inflammatory peptides grab on to the whiskers of atherogenic oxidized lipids
  307. Antioxidant and cholesterol lowering properties of 2, 6-di-t-butyl-4-[(dimethylphenylsilyl) methyloxy] phenol and derivatives: a new class ofย ANTI-ATHEROGENICโ€ฆ
  308. Cholesteryl Ester Transfer Protein Genotype Predictsย ANTI-ATHEROGENICLipid Profile and Decreased Risk of Ishemic Heart Disease, Ischemic Cerebrovascular Disease โ€ฆ
  309. eNOS-NO system contributes to a novelย ANTI-ATHEROGENICeffect of Leonurine via inflammation inhibition and plaque stabilization
  310. Effect of anย ANTI-ATHEROGENICdiet, including soy protein products with various levels of phytoestrogens, on indicators of humoral immunity in patients with hypertension โ€ฆ
  311. Intervention with anti-inflammatory RVE1 attenuates atherosclerosis without decreasing plasma cholesterol and adds to theย ANTI-ATHEROGENICeffect of atorvastatin
  312. ANTI-ATHEROGENICeffect of NIP-200 on the experimental atherosclerosis in cholesterol-fed rabbits
  313. ANTI-ATHEROGENICactions of (+)-catechin
  314. 0383: anti-inflammatory andย ANTI-ATHEROGENICeffects of the inflammasome NLRP3 inhibitor, arglabin, in ApoE2Ki mice fed a high fat diet
  315. Chemical Composition, Anti-neuraminidase, andย ANTI-ATHEROGENICActivities of the Essential Oil from two Varieties of Alpinia zerumbet Leaves
  316. Endothelial lipase exerts itsย ANTI-ATHEROGENICeffect through increased catabolism of ฮฒ-VLDLS
  317. Insulin-like growth factor-1 upregulates junction proteins in vascular endothelial cells: potential mechanisms forย ANTI-ATHEROGENICeffect of insulin-like growth factor-1
  318. ANTI-ATHEROGENICEffect of Oleanolic Acid Appears Unrelated to Endothelial Release of Nitric Oxide
  319. A new antiโ€atherogenic strategy
  320. ANTI-ATHEROGENICactions of dihomo-gamma-linolenic acid in macrophages
  321. Pioglitazone treatment may lead toย ANTI-ATHEROGENICalterations of lipoproteins through increasing serum adiponectin in statin-treated diabetes patients
  322. ANTI-ATHEROGENICAction of Eicosapentaenoic Acid
  323. Loss of macrophage LDL receptor related protein 1 (LRP1) confers resistance to theย ANTI-ATHEROGENICeffects of TNFฮฑ inhibition
  324. ANTI-ATHEROGENICDiets: Observations from Mouse Models
  325. Adoptive Cell Transfer Demonstrates that CD8+ T cells Mediate theย ANTI-ATHEROGENICEffects of the ApoB-100 Peptide P210 Immunization in ApoEโˆ’/โˆ’ Mice
  326. ADENOVIRAL EXPRESSION OF HUMAN LCAT IN NON-HUMAN PRIMATES LEADS TO ANย ANTI-ATHEROGENICLIPOPROTEIN PHENOTYPE BY โ€ฆ
  327. Disturbed Flow-Targeting Nanovesicles forย ANTI-ATHEROGENICTheragnosis
  328. ANTI-ATHEROGENICeffects of resveratrol via liver X receptor a-dependent upregulation of ATP-binding cassette transporters A1 and G1 in macrophages
  329. Anti-inflammatory andย ANTI-ATHEROGENICEffects of Lactobacillus plantarum in Hypercholesterolemic Mice
  330. ANTI-ATHEROGENICactions of dihomo-gamma-linolenic acid and its key metabolites
  331. Sphingosine 1-phosphate (S1P) receptor type 1 signaling induces anย ANTI-ATHEROGENICphenotype in macrophages and attenuates atherosclerosis in LDL-receptor โ€ฆ
  332. Involvement of Vascular Endothelial Cells in theย ANTI-ATHEROGENICEffects of Liraglutide in Diabetic Apolipoprotein E-null Mice
  333. Anti-inflammatory, antioxidative andย ANTI-ATHEROGENICbioactivity in marine sources ascribed to nonlipid constituents
  334. The role of the ERK1: STAT1 serine 727 phosphorylation axis on key atherosclerosis associated cellular processes and theย ANTI-ATHEROGENICactions of hydroxytyrosol
  335. Fish and camelina sativa oil: effects on fatty acid composition of blood lipid fractions, lipoprotein subclasses and pro-andย ANTI-ATHEROGENIClipoprotein functions
  336. Antihypercholesterolemic, antioxidative and anti-inflammatory potential of an extract of the plant Tabernaemontana divaricata in experimental rats fed an atherogenic โ€ฆ
  337. ANTI ATHEROGENICEffects of Micro RNA-21
  338. Ateronon: First clinically provenย ANTI-ATHEROGENICantioxidant
  339. Atherogenic andย ANTI-ATHEROGENICrisk markers in subjects with obesity and/or type 2 diabetes
  340. ANTI-ATHEROGENICEffect of Nuts: Is the Answer NO?-Reply
  341. Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents
  342. THE ANTI-INFLAMMATORY AND POTENTIALย ANTI-ATHEROGENICEFFECT OF INSULIN
  343. Vascular endothelial expression of atherogenic andย ANTI-ATHEROGENICproteins in humans: Relations to cardiovascular disease risk factors
  344. Anti-inflammatory andย ANTI-ATHEROGENICrole of IL-32ฮฑ in vascular endothelium
  345. Plasma level of atherogenic andย ANTI-ATHEROGENICfactors among palm wine drinkers of rural Southwest Nigeria
  346. Application of the cDNA array system for screeningย ANTI-ATHEROGENICagents
  347. Testing of antiโ€atherogenic drugs on cell cultures: reliability questioned
  348. Evaluation ofย ANTI-ATHEROGENICeffects of P2Y12 receptor antagonists in Apolipoprotein E-deficient mice
  349. In vivo antioxidant action andย ANTI-ATHEROGENICeffect of a novel antioxidant (BO-653)
  350. ANTI-ATHEROGENICproperties of HDL: Insights from the AIMilano mutation
  351. IgM autoantibodies against lipoprotein (A) as an โ€œANTI-ATHEROGENICโ€ factor in patients with severe hyperlipidemia
  352. Abstract# 2703: Anti-carcinogenic andย ANTI-ATHEROGENICpotential of dietary phytochemicals
  353. ANTI-ATHEROGENICProperties of Heme Oxygenase
  354. Antiโ€atherogenic Effect of T0901317 Nanovesicles in THPโ€1 Derived Macrophages
  355. Mountain tea (Sideritis plants): A potentialย ANTI-ATHEROGENICagent?
  356. Erratum to: Cell Culture as a Testing System forย ANTI-ATHEROGENICSubstances: A Brief Communication
  357. PROGNOSTIC IMPLICATIONS OF ATHEROGENIC/ANTI-ATHEROGENICLIPID RATIOS IN AN ETHNICALLY DIVERSE POPULATION.
  358. OP22 The impact of estrogen on theย ANTI-ATHEROGENICeffect of H2S
  359. MECHANISMS OF ACTION OF PHENOLIC COMPOUNDS FOCUSES ON THEIR ANTI-OXIDATIVE ANDย ANTI-ATHEROGENICEFFECTS
  360. ANTI-ATHEROGENICEffects of Cureumin in Hypercholesterolemic Rabbits
  361. ANTI-ATHEROGENICeffects of dietary supplementation of Kgengwe (Citrullus lanatus) seed powder in low density lipoprotein receptor knock-out mice
  362. Identification ofย ANTI-ATHEROGENICand Anti-inflammatory Effects of Walnuts and Pistachios
  363. Effect of heating on theย ANTI-ATHEROGENICaction of sunflower oil.
  364. Anti-inflammatory andย ANTI-ATHEROGENICeffects of 9E,11E-conjugated linoleic acid
  365. Rosemary asย ANTI-ATHEROGENICfood ingredient
  366. ANTI-ATHEROGENICmechanisms of berberine
  367. Long term hypolipidaemic andย ANTI-ATHEROGENICeffects ofCarica papaya Linn. administration on normal rabbits
  368. Antiโ€atherogenic effect of blueโ€green algae in male apolipoprotein E knockout mice fed an atherogenic diet
  369. Novelย ANTI-ATHEROGENICeffects of MH13 in vascular smooth muscle cells
  370. Study on Effects of Food Factors andย ANTI-ATHEROGENICLipoprotein Function (Young Investigator Award of JSFNS (2013))
  371. Lipoprotein interactions with the arterial wall: Pro-vs.ย ANTI-ATHEROGENICeffects
  372. Therapeutic strategies in management of atherosclerosis by manipulation ofย ANTI-ATHEROGENICB1a lymphocytes
  373. ANTI-ATHEROGENICeffect of circylating immune complexes in schistosomal hepatic fibrosis
  374. Antiโ€atherogenic effect of dandelion extracts through antiโ€inflammatory and antiโ€oxidative processes in C57BL/6 mice
  375. ANTI-ATHEROGENICpotential of ฮณ-linolenic acid.
  376. ANTI-ATHEROGENICeffect of calcium antagonist plus statin cotreatment realises at lipoprotein level
  377. ANTI-ATHEROGENICeffects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase 2 independent mechanisms 3
  378. Different association of serum docosahexaenoic acid and eicosapentaenoic acid levels with atherogenic andย ANTI-ATHEROGENIClipoproteins in statin-treated diabetes โ€ฆ
  379. Physicochemical characteristics of rapidly dried onion powder and itsย ANTI-ATHEROGENICeffect
  380. A Study of Antiobesity, Hypolipidemic andย ANTI-ATHEROGENICActivity of Poly Herbal Formulation against High Fat Diet-Induced Obesity in Albino Rats
  381. ANTI-ATHEROGENICEffects of the Methanol Extract of Sorbus Cortex in Atherogenic-Diet Rats (Pharmacognosy)
  382. Comparison of theย ANTI-ATHEROGENICand Anti-metabolic Effects Between Miglitol and Nteglinide in Diabetic Patients with Coronary Artery Disease
  383. Thromboxane receptor blockade improves theย ANTI-ATHEROGENICeffect of
  384. ANTI-ATHEROGENIC, Anti-Inflammatory, and Anti-Hypertensive Effects of Peanuts Determined with In Vivo and In Vitro Models
  385. ANTI-ATHEROGENICeffect of enterosorption in patients with diabetes mellitus
  386. Theย ANTI-ATHEROGENICActivity of Luteolin and Luteolin-7-O-glucoside in High-Fat Diet-Administered Hyperhomocysteinemia-Induced C57BL/6J Mice
  387. Novel pro-andย ANTI-ATHEROGENICeffects of apolipoprotein B-containing lipoproteins: To feast or to fast?
  388. ANTI-ATHEROGENICeffect of circulating immune complexes in schistosomal hepatic fibrosis
  389. Fish oil supplementation inducesย ANTI-ATHEROGENICgene expression profiles in human blood mononuclear cells
  390. Anti-Inflammatory andย ANTI-ATHEROGENICActivities of Ncx 6560, a Nitric Oxide (no)-Donating Statin, in Hypercholesterolemic Mice
  391. ANTI-ATHEROGENICEffects of Functional Sujeonggwa Drinks in Hypercholesterolemic Apo E KO Mice
  392. ANTI-ATHEROGENICAND ANTI-ANGIOGENIC EFFECTS OF DONEPEZIL, A DRUG FOR ALZHEIMERโ€™S DISEASE
  393. Analysis of the Molecular Organization of Lipoprotein-Associated Apolipoprotein E, anย ANTI-ATHEROGENICProtein
  394. CYP1A1 and CYP1B1 expression and free zinc levels in endothelial cells are differentially regulated by pro-atherogenic versusย ANTI-ATHEROGENICshear stress
  395. Studies on the Pathogenesis of Atherosclerosis and Development ofย ANTI-ATHEROGENICSmall Molecule Using Gene Targeted Mouse
  396. Hypolipidemic and antiโ€atherogenic effect of omegaโ€3 enriched structured lipids from linseed oil (LSO) with refined palm olein oil (RPOO) on rats fed atherogenic diet
  397. Platycodin D lowers cholesterol in vivo and hasย ANTI-ATHEROGENICproperties in vitro
  398. Apolipoprotein B Bound To Erythrocytes: A Novelย ANTI-ATHEROGENICLipid Transport Pathway
  399. < The> metabolic effect of partial lipectomy in old aged rats and the associated changes in theย ANTI-ATHEROGENICindex: adiponectin/leptin ratio
  400. ANTI-ATHEROGENICfunction of LPL in human and porcine coronary endothelial cells
  401. Comparison theย ANTI-ATHEROGENICand hypolipidaemic effect of Cod liver oil, pomegranate seed oil and Rosuvastatin in hyperecholestrolemic rats
  402. Pro-andย ANTI-ATHEROGENICeffects of a dominant negative P465L mutation of PPARฮณ in apolipoprotein E-null mice
  403. ANTI-ATHEROGENICEffect of Novel Peroxisome Proliferator-Activated Receptor ฮด Agonist RSC-451061 Hydrochloride Accompanied by Anti-Inflammatory Effects in LDL โ€ฆ
  404. Statin treatment potentiates the lipid-lowering andย ANTI-ATHEROGENICeffect of bat activation by accelerating lipoprotein remnant clearance
  405. HDL and ABC Transporters Reduce the Proliferation of Hematopoietic Stem and Progenitor Cells, withย ANTI-ATHEROGENICConsequences
  406. ANTI-ATHEROGENICproperties of paraoxonase 2 and paraoxonase 3: In vitro and in vivo studies
  407. Kruppel-like factors: emerging regulators mediating theย ANTI-ATHEROGENICeffects of flow shear stress
  408. FENOFIBRATE-MEDIATEDย ANTI-ATHEROGENICACTIVITY: LONG-TERM FOLLOW-UP STUDY OF RHEUMATOID ARTHRITIS PATIENTS BY COMPARING โ€ฆ
  409. 11: THE ADENOSINE A2A RECEPTOR AGONIST UK-432,097 STIMULATESย ANTI-ATHEROGENICREVERSE CHOLESTEROL TRANSPORT PROTEINS IN THP-1 โ€ฆ
  410. The Role of Scavenger Receptor-A in Heat Shock Protein 27-mediated Atheroprotection: Mechanistic Insights into a Novelย ANTI-ATHEROGENICTherapy
  411. Novel antiโ€atherogenic effects of trivalent chromium in vascular smooth muscle cells: therapeutic implication for diabetic vascular complications
  412. Schistosoma Mansoni infection inducesย ANTI-ATHEROGENICtranscriptional changes in hepatic macrophages (MPF2P. 758)
  413. Nanoencapsulation Enhances Epigallocatechin Gallate (EGCG) Stability and Itsย ANTI-ATHEROGENICBioactivities in Macrophages
  414. 66-mercaptopurine inducesย ANTI-ATHEROGENICeffects in monocytes/macrophages and inhibits
  415. eNOS-NO system attributes to novelย ANTI-ATHEROGENICeffect of leonurine via inflammation inhibition and plaque stabilization
  416. ANTI-ATHEROGENICand Nephroprotective Effects of Tocotrienol Rich Fraction (TRF) from Palm Oil and Rice Bran Oil
  417. ANTI-ATHEROGENICeffects of long term benfluorex treatment in insulino-resistant Sand rats (Psammomys obesus)
  418. ANTI-ATHEROGENICEffects of Hexane Extracts of Yam, Dioscorea batatas Decne
  419. In vitro radical scavenging activity of short arm octopus added kimchi and itsย ANTI-ATHEROGENICeffects in Apo E KO mice
  420. ANTI-ATHEROGENICAND ANTIOXIDANT POTENCY OF TINOSPORA CRISPA IN RABBITS FED WITH HIGH FAT DIET.
  421. Change of natural antibody levels in patients with cardiovascular diseases by the use ofย ANTI-ATHEROGENICdiets with processed soy product foods
  422. Inhibition of Cytokine Induced I-B Kinase Activation as a Mechanism Contributing to theย ANTI-ATHEROGENICActivity of Tilianin in Hyperlipidemic Mice
  423. The effect of antibodies against high-density lipoprotein (aHDL) and apolipoprotein AI (aApo AI) on theย ANTI-ATHEROGENICand anti-inflammatory properties of HDL in โ€ฆ
  424. Niacin improvesย ANTI-ATHEROGENICeffect of statins in APOE* 3Leiden. CETP mice
  425. Functional interplay between LXR and AMPK inhibits atherosclerosis in apoE deficient miceโ€”โ€”A newย ANTI-ATHEROGENICstrategy
  426. Assessment ofย ANTI-ATHEROGENICdrugs in vivo and reconstitution of lipoproteins using radioiodinated cholesteryl iopanoate
  427. Beyond LDL Cholesterol: Carriers of the PCSK9 R46L Variant Are Characterized by anย ANTI-ATHEROGENICLipoprotein Profile Assessed by Nuclear Magnetic โ€ฆ
  428. Viralย ANTI-ATHEROGENICProteins Alter Monocyte and Neutrophil Invasion in Mice and Bag3 Gene Expression
  429. Bone Marrow Angiotensin AT2 Receptor Deficiency Aggravates Atherosclerosis by Eliminating Macrophage Liver X Receptor-Mediatedย ANTI-ATHEROGENICActions
  430. Opuntiol and opuntioside-I anย ANTI-ATHEROGENICagent interfering with chemotaxis via IPLA2B-dependent F-actin polymerization in human monocyte
  431. Molecular Pathology: Poster# 247 OPUNTIOL AND OPUNTIOSIDE-I ANย ANTI-ATHEROGENICAGENT INTERFERING WITH CHEMOTAXIS VIA IPLA2B-DEPENDENT โ€ฆ
  432. English walnut (Juglans regia) and human immune function: Support of theย ANTI-ATHEROGENICproperties of walnuts and identification of a new link in โ€ฆ
  433. Combination Therapy with Olmesartan and Azelnidipine Exertsย ANTI-ATHEROGENICEffects in Diabetic Apolipoprotein E-Deficient Mice
  434. VIRALย ANTI-ATHEROGENICPROTEINS ALTER MONOCYTE AND NEUTROPHIL INVASION IN MICE WITH ALTERED BAG3 GENE EXPRESSION
  435. Resveratrol Protects against Atherosclerosis, but Does not Add to theย ANTI-ATHEROGENICEffect of Atorvastatin, in APOE* 3-Leiden. CETP Mice
  436. Cilostazol Selectively Increasesย ANTI-ATHEROGENICHDL Subclass (LpA-I particles) in Male Patients with Non-insulin Dependent Diabetes Mellitus
  437. โ€ฆ of Differentially Expressed Genes in the Aortae of Apoe-deficient Mice Infused with Insulin-like Growth Factor I: Novel Mechanisms of theย ANTI-ATHEROGENICEffect of IGF โ€ฆ
  438. Supplementary Material to Conditional linkage and genome-wide association studies identify UGT1A1 as major gene forย ANTI-ATHEROGENICserum bilirubin levelsโ€“a โ€ฆ
  439. ANTI-ATHEROGENICproperties associated with the antioxidant activity from the hydrophilic extracts of Halimeda incrassata (Chlorophyta, Bryopsidales)
  440. The antiโ€atherogenic potential of Cโ€type natriuretic peptide: Disparate regulation of endothelial and vascular smooth muscle cell proliferation via natriuretic peptide โ€ฆ
  441. Apolipoprotein J (clusterin) induces cholesterol export from macrophage foam cells: A potentialย ANTI-ATHEROGENICfunction?
  442. โ€ฆ T Lymphocytes Recruitment by Inhibiting T Lymphocytotropic CXC Chemokines in LPS-Stimulated Macrophages: A Potentialย ANTI-ATHEROGENICFunction of Adiponectin
  443. Attenuatedย ANTI-ATHEROGENICEffects by Statins in Diabetic Patients in Comparison with Non-diabetic Patients; Non-invasive Quantitative Analysis of Coronary โ€ฆ
  444. Is the Post-menopausal Rise in PCSK9 Levels Due to Loss of the Estrogen Responsiveย ANTI-ATHEROGENICProtein, Heat Shock Protein 27? Insights Into a Potential New โ€ฆ
  445. Circulating Markers Reflect Both Anti-and Pro-Atherogenic Drug Effects in ApoE-Deficient Mice
  446. Immunomodulatory and anti-angiogenic properties of Linum usitatissium (flaxseed) seeds ethanolic extract in atherogenic diet treated rats
  447. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
  448. Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE* 3Leiden. CETP mice
  449. ApolipoproteinA1-75 G/A (M1-) polymorphism and lipoprotein (a); anti-vs. pro-atherogenic properties
  450. Anti-obesity potential of almond (Prunus dulcis) in experimental animals under cafeteria and atherogenic diets
  451. Malvidin 3-glucoside, a dietary anthocyanin, contributes to the balance between pro-and anti-inflammatory mediators in human endothelial cells: a potential role โ€ฆ
Related Posts

Lipolysis (The Decomposition Of Body Fat)

BIOMIMETIC HYDROXYAPATITE

Cold-inducible Rna-binding Protein (Cirbp) & Dna Repair

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping